Cargando…

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

BACKGROUND: The recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20–40% of patients experience a complete pathological response (pCR) in the RC specimen and these patients have e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinsenveld, F. J., Noordman, B. J., Boormans, J. L., Voortman, J., van Leenders, G. J. L. H., van der Pas, S. L., van Beek, S. C., Oprea-Lager, D. E., Vis, A. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556888/ https://www.ncbi.nlm.nih.gov/pubmed/34715822 http://dx.doi.org/10.1186/s12885-021-08840-2

Ejemplares similares

Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case–control matching study
por: van Ginkel, Noor, et al.
Publicado: (2022)

Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
por: Beije, N., et al.
Publicado: (2022)

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays
por: de Jong, Joep J., et al.
Publicado: (2021)

Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
por: van Hoogstraten, L. M. C., et al.
Publicado: (2021)

Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value
por: Vaneman, Jasmijn, et al.
Publicado: (2023)

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer
por: van Kessel, Kim E.M., et al.
Publicado: (2016)

External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
por: Brinkmann, Sebastian, et al.
Publicado: (2019)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Attenuated XPC Expression Is Not Associated with Impaired DNA Repair in Bladder Cancer
por: Naipal, Kishan A. T., et al.
Publicado: (2015)

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
por: van Hoogstraten, Lisa M. C., et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

PatientVOICE: Development of a Preparatory, Pre-Chemotherapy Online Communication Tool for Older Patients With Cancer
por: van Dulmen, Sandra, et al.
Publicado: (2017)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?
por: Beukers, Willemien, et al.
Publicado: (2012)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
por: Cowan, N. G., et al.
Publicado: (2014)

E17K substitution in AKT1 in prostate cancer
por: Boormans, J L, et al.
Publicado: (2010)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
por: Faneyte, I F, et al.
Publicado: (2003)

Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study
por: Leimkühler, M., et al.
Publicado: (2019)

Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review
por: Khoraminia, Farbod, et al.
Publicado: (2023)

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
por: Noordman, Bo Jan, et al.
Publicado: (2015)

Smoking status and pathological response to neoadjuvant chemotherapy among patients with bladder cancer: a pooled analysis
por: He, Tongchen, et al.
Publicado: (2021)

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study
por: Balmativola, D., et al.
Publicado: (2014)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

The Role of Pathology in Small Renal Mass Laparoscopic Cryoablation
por: Lagerveld, B. W., et al.
Publicado: (2012)

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer
por: Ali, H. Raza, et al.
Publicado: (2016)

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial
por: Rutten, V. C., et al.
Publicado: (2023)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder
por: van Doeveren, Thomas, et al.
Publicado: (2020)

Bladder endometriosis, a remarkable resemblance in a monozygotic twin
por: van Beek, J. J.
Publicado: (2009)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
por: Font, Albert, et al.
Publicado: (2020)

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
por: Goedegebuure, R.S.A., et al.
Publicado: (2021)

Cylindroma, an uncommon presentation on (18)F-DCFPyL PET/CT
por: Koene, B. P. F., et al.
Publicado: (2020)

The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy
por: Cullinane, C., et al.
Publicado: (2022)

Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: de Jongh, M, et al.
Publicado: (2021)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9ciab1m8ollv9vuu46sdq3e0gp